Things to consider about DUROLANE:

  • Significant reduction in knee pain up to 6 months4
  • Significant reduction in need for analgesic use up to 9 months4
  • Reduced NSAID use up to 6 months4
  • DUROLANE is covered by most insurance companies36

Introduction to DUROLANE

Learn more about DUROLANE

Summary of Indications: DUROLANE (3ml): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been licenced for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes.

DUROLANE SJ (1ml): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, fingers and toes. Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in product labeling, or by clicking the Instructions for Use link located at the bottom of the page.